Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in unmet need areas. Co.'s product candidate, Tebipenem Pivoxil Hydrobromide, is designed to be an oral carbapenem-class antibiotic for use in adults to treat involving multi-drug resistant (MDR) Gram-negative infections. Co. is also developing SPR720, an oral antibiotic designed for the treatment of an orphan disease caused by non-tuberculous mycobacterial pulmonary infections. Co. is advancing SPR206, a polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. The SPRO stock yearly return is shown above.
The yearly return on the SPRO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SPRO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|